MYC/TET3‐Regulated TMEM65 Activates OXPHOS‐SERPINB3 Pathway to Promote Progression and Cisplatin Resistance in Triple‐Negative Breast Cancer
Advanced Science · 2025
DOI: 10.1002/advs.202500421 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2025. Verfasst von Yin-Ling Zhang und 10 weiteren Autor:innen. Beteiligte Einrichtung: Fudan University Shanghai Cancer Center and Institutes of Biomedical Sciences, Fudan University, Shanghai, 200032, China. Hauptthemen laut MEDLINE: Triple Negative Breast Neoplasms, Cisplatin, Membrane Proteins, Drug Resistance, Neoplasm. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 83 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: China Postdoctoral Science Foundation, Basic and Applied Basic Research Foundation of Guangdong Province, Natural Science Foundation of Shanghai Municipality.
Abstract (Originalsprache)
Triple‐negative breast cancer (TNBC) is the most lethal subtype of breast cancer due to its aggressive clinical features and the lack of effective targeted therapeutics. Mitochondrial metabolism is intimately linked to TNBC progression and therapeutic resistance and is an attractive therapeutic target for TNBC. Here, it is first reported that human transmembrane protein 65 (TMEM65), a poorly characterized mitochondrial inner‐membrane protein‐encoding gene in human cancer, acts as a novel oncogene in TNBC to promote tumor growth, metastasis, and cisplatin resistance both in vivo and in vitro. Transcription factor MYC and DNA demethylase ten‐eleven translocation 3 (TET3) coordinately upregulate TMEM65 in TNBC, and its upregulation is associated with poor patient survival. Moreover, pharmacological inhibition or knockdown of MYC and TET3 attenuates TMEM65‐driven TNBC progression. Mechanistic investigations reveal that TMEM65 enhances mitochondrial oxidative phosphorylation and its byproduct reactive oxygen species (ROS) production. Increased ROS induces the expression of hypoxia‐inducible factor 1α (HIF1α), which in turn transcriptionally activates serpin family B member 3 (SERPINB3) to enhance TNBC stemness, thus leading to TNBC progression and cisplatin resistance. Collectively, these findings identify TMEM65 as a vital oncogene of TNBC, unveil its regulatory mechanisms, and shed light on its potential role in TNBC therapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Fudan University Shanghai Cancer Center and Institutes of Biomedical Sciences, Fudan University, Shanghai, 200032, China.
- Cancer Institute, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
- Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
- Shanghai Key Laboratory of Breast Cancer, Shanghai Medical College, Fudan University, Shanghai, 200032, China.
- Precision Cancer Medicine Center, Fudan University Shanghai Cancer Center, Shanghai, 200032, China.
- Department of Oncology, The Second Affiliated Hospital, Guangzhou Medical University, Guangzhou, Guangdong, 510260, China.
ORCID-Profile: Da-Qiang Li
Förderung
- China Postdoctoral Science Foundation
- Basic and Applied Basic Research Foundation of Guangdong Province
- Natural Science Foundation of Shanghai Municipality
- National Natural Science Foundation of China
Zitieren
APA
Zhang, Y. L., Huang, M. Y., Yang, S. Y., Cai, J. Y., Zhao, Q., Zhang, F. L., Hu, X., Shao, Z. M., Liao, L., Cao, A. Y., & Li, D. Q. (2025). MYC/TET3‐Regulated TMEM65 Activates OXPHOS‐SERPINB3 Pathway to Promote Progression and Cisplatin Resistance in Triple‐Negative Breast Cancer. Advanced Science. https://doi.org/10.1002/advs.202500421
Vancouver
Zhang YL, Huang MY, Yang SY, Cai JY, Zhao Q, Zhang FL, et al. MYC/TET3‐Regulated TMEM65 Activates OXPHOS‐SERPINB3 Pathway to Promote Progression and Cisplatin Resistance in Triple‐Negative Breast Cancer. Advanced Science. 2025. doi:10.1002/advs.202500421
BibTeX
@article{Zhang2025,
author = {Zhang, Yin-Ling and Huang, Min-Ying and Yang, Shao-Ying and Cai, Jia-Yang and Zhao, Qian and Zhang, Fang-Lin and Hu, Xin and Shao, Zhi-Min and Liao, Li and Cao, A-Yong and Li, Da-Qiang},
title = {MYC/TET3‐Regulated TMEM65 Activates OXPHOS‐SERPINB3 Pathway to Promote Progression and Cisplatin Resistance in Triple‐Negative Breast Cancer},
journal = {Advanced Science},
year = {2025},
doi = {10.1002/advs.202500421}
}
EUVIMED